O #Zasocitinib obteve uma taxa PASI 100 >2,5x superior ao deucravacitinib num ensaio fase 3 direto de #psoríase, com segurança consistente e dose oral única diária.
www.ipharmacenter.com/post/takeda-...
#notícias #farma #saúde #pharma #healthcare #globalhealth #lifesciences
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
